In Crowded Field Of Psychedelic Startups, Filament CEO Makes Case For ‘Natural’ Drugs
Benjamin Lightburn, CEO of Filament, is pictured.
A recent boom in psychedelic research has given way to a bumper crop of startups seeking to harness the potential of mind-altering drugs for treating…


